Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens–Johnson syndrome: Our current understanding
Section snippets
Summary
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe adverse drug reactions characterized by a low incidence but high mortality. The incidence of SJS is approximately 6 cases per million persons per year, and that of TEN is approximately 2 cases per million persons per year [1]. However, SJS and TEN are idiosyncratic in nature and thereby have the potential to affect any individual taking a medication; the most frequently incriminated drugs being antibiotics,
References (17)
- et al.
Severe adverse cutaneous reactions to drugs
N Engl J Med
(1994) - et al.
Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme
Arch Dermatol
(1993) - et al.
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis
J Invest Dermatol
(2000) - et al.
Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States
Arch Dermatol
(2004) - et al.
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
Br J Dermatol
(1996) - et al.
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule
Nat Immunol
(2000) - et al.
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
Science
(1998) - et al.
Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience
Dermatology
(2001)
Cited by (104)
Necroptotic and apoptotic cell death in Toxic Epidermal Necrolysis
2021, Journal of Dermatological ScienceToxic epidermal necrolysis: Pathophysiology and therapeutic advances
2017, Revue Francaise d'AllergologieA review of toxic epidermal necrolysis management in Japan
2017, Allergology InternationalRetrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients - Treatment and outcome
2016, Allergology InternationalCitation Excerpt :However, the effect of IVIG is still controversial.31,32 In 2006, French et al. summarized the clinical studies reported and suggested that the use of more than 2 g/kg of body weight of intravenous immunoglobulin is beneficial on the mortality associated with TEN.9 Barron et al.33 conducted a meta-analysis with meta-regression of 13 observational studies conducted during the period of 1966–2011 to assess IVIG in the treatment of SJS/TEN based on the SCORTEN scoring system.
A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres
2014, BurnsCitation Excerpt :Since then, the use of IVIG has become more frequent in the treatment of TEN. A meta-analysis of nine studies evaluating the impact of IVIG on mortality concluded that at high doses of IVIG (>2 g/kg) a 59% reduction between expected and observed mortality rate was detected, compared to a 3% reduction in low doses of IVIG [56]. Considering the studies included in this review, we noted a rise in the use of IVIG since 1999.